English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

PACCEZ, J.D. Genetically modified Bacillus subtilis strains applied in the development of mucosal vaccines against enteric pathogens. 2007. Doctor thesis (Microbiologia) – Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, 2007. Bacillus subtilis is a gram positive, generally regarded as safe and spore forming soil bacteria used as a model for genetic and phisiological studies. This safety status allow its use as host for production of industrial protases and its application as vaccine vehicles, however the lack of epissomal inducible expression systems disable the exploration of this organism as a biotechnologic tool. In this work we describe the construction of epissomal vectors able to express the B subunit of the heat-labile toxin (LTB) and the structural subunit of the CFA/I fimbrae (CFAB) from the enterotoxigenic Escherichia coli (ETEC). We evaluate strains able to express LTB under the control of three promoters: PgsiB (stress inducible), PlepA (constitutive) e Pspac (IPTG inducible) and allowing the expression of LTB secreted or anchored to the cell wall We also evaluate the immunogenicity of strains able to co-express LTB and the listeriolysin O (LLO) from Listeria monocytogenes. CFAB was expressed in the cytoplasm or anchored to the cell wall and administred alone or with the mucosal adjuvant LT. Mice immunized both with cells or spores elicited secreted and systemic specific antibodies responses, which were not altered by the addition of the adjuvant LT. LLO expression suppressed the antibodies responses against LTB. The data shows the ability of B. subtilis to be used as vaccine vehicle.

Aplicação de linhagens geneticamente modificadas de Bacillus subtilis no desenvolvimento de vacinas de mucosas contra patógenos entéricos.